Overview

BK With VST for Kidney Transplant Patients

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

This study measures the safety, feasibility, and efficacy of viral-specific T cells (VST) against BK Virus (BKV) in adult kidney transplant recipients. Participants are expected to be on study for 52 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

University of Wisconsin, Madison